Blood: Avelumab treats recurrent/incurable NK/T cell lymphoma.

PD-1/PD-L1 immunotherapy is a kind of anti-cancer immunotherapy that has attracted worldwide attention and revolutionized tumor treatment, bringing new hope to patients, and aims to make full use of the body's own immune system to fight and fight cancer, and has the potential to treat many types of tumors by blocking the PD-1/PD-L1 signaling path.
Avelumab, the fourth approved PD-1/PD-L1 antibody, was approved by the FDA in March 2017 for the treatment of metastatic merkel cell carcinoma.
study (NCT03439501) was designed to evaluate the efficacy and safety of avelumab for recurrent/incurable out-of-knot natural killers (NK)/T-cell lymphoma (ENKTL).
The study was a Phase II clinical trial that recruited 21 patients with recurrent/incurable ENKTL to be treated with avlumab (10 mg/kg, 28 days/course of treatment, day 1 and day 15).
end point is the Complete Mitigation (CR) rate.
addition, the researchers conducted targeted sequencing and immunogroup analysis of tumor tissue and blood samples before and after treatment to detect cytokines, PD1, PD-L1, and PD-L2.
CR rate was 24% (5/21) and the overall mitigation rate was 38% (8/21).
although the non-responders showed early progress, the five respondents were still receiving treatment and their remission continued.
most treatment-related adverse reactions are 1/2 level, no 4 adverse reactions.
the therapeutic response was independent of serum levels of mutation spectrum, tumor mutation load, cytokines, or soluble PD1/PD-L1/PD-L2.
the response to avelumab therapy was significantly associated with the expression of PD-L1 in tumor tissue (p.001).
therefore, tumor tissue in all patients receiving CR had high expression of PD-L1, and tumor substations based on PD-L1 expression were associated with therapeutic responses.
, avelumab exhibited single-drug activity in some recurrent/incurable ENKTL patients.
evaluation of the expression of PD-L1 in tumor cells may help screen patients who are sensitive to avelumab.
.